Berkshire Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-2,153
Closed -$204K 211
2019
Q4
$204K Buy
+2,153
New +$193K 0.02% 193
2019
Q3
Sell
-2,496
Closed -$228K 221
2019
Q2
$228K Sell
2,496
-544
-18% -$46K 0.02% 193
2019
Q1
$262K Sell
3,040
-335
-10% -$26.9K 0.02% 196
2018
Q4
$259K Sell
3,375
-360
-10% -$28K 0.02% 188
2018
Q3
$288K Buy
3,735
+308
+9% +$22.8K 0.02% 192
2018
Q2
$232K Buy
3,427
+150
+5% +$10.4K 0.02% 195
2018
Q1
$237K Sell
3,277
-1,757
-35% -$134K 0.02% 187
2017
Q4
$379K Buy
5,034
+1,819
+57% +$137K 0.04% 162
2017
Q3
$247K Buy
+3,215
New +$243K 0.03% 171
2016
Q4
Sell
-24,729
Closed -$1.75M 184
2016
Q3
$1.75M Buy
24,729
+7,056
+40% +$514K 0.25% 75
2016
Q2
$1.31M Buy
+17,673
New +$1.22M 0.2% 79
2016
Q1
Sell
-4,117
Closed -$317K 163
2015
Q4
$317K Buy
4,117
+738
+22% +$58.6K 0.05% 126
2015
Q3
$278K Buy
3,379
+471
+16% +$41.9K 0.05% 129
2015
Q2
$256K Buy
+2,908
New +$267K 0.04% 142

Other funds holding NVS

Berkshire Asset Management's NVS Position: Q1 2020 in Review

Berkshire Asset Management sold out of Novartis (NVS) in Q1 2020, closing a stake of 2,153 shares — an estimated $204K sold.

Berkshire Asset Management first reported a position in NVS in Q2 2015 and held it in 14 quarters. The position peaked at $1.75M in Q3 2016. 1,133 funds tracked by Wall St. Rank hold NVS as of Q1 2020.

  • Berkshire Asset Management reported no remaining Novartis position as of Q1 2020 after selling out during the quarter.
  • Berkshire Asset Management sold 2,153 Novartis shares in Q1 2020, an estimated $204K.
  • Berkshire Asset Management first reported a position in Novartis in Q2 2015 and held it in 14 quarters.
  • Berkshire Asset Management's Novartis position peaked at $1.75M in Q3 2016.
  • 1,133 funds tracked by Wall St. Rank held Novartis as of Q1 2020.

Based on Berkshire Asset Management's 13F filing for Q1 2020, filed 13 May 2020.